Content on this webpage is provided for historical information about the NIH Clinical Center. Content is not updated after the listed publication date and may include information about programs or activities that have since been discontinued.
Dr. James K. Gilman presents a certificate of appreciation to Dr. Charles L. Sawyers.
Dr. Charles L. Sawyers, a Howard Hughes Medical Institute investigator, the Marie-Josée and Henry Kravis Chair in Human Oncology and Pathogenesis, and chairman, Human Oncology and Pathogenesis Program, at the Memorial Sloan Kettering Cancer Center, was recognized as the 2017 Distinguished Clinical Research Scholar and Educator in Research - the fifth to be honored.
As part of the award, Sawyers a world-renowned cancer physician-scientist who studies mechanisms of cancer drug resistance with the goal of developing novel therapies, presented the Clinical Center Grand Rounds lecture Feb. 8, "The Changing Landscape of Cancer Drug Resistance."
Sawyers, who co-discovered the antiandrogen drug enzalutamide approved by the US Food and Drug Administration in 2012 for treatment of advanced prostate cancer, discussed the different mechanisms of drug resistance and the history of the research around drug resistance.
Following the lecture, Dr. James K. Gilman, chief executive officer of the NIH Clinical Center, presented a certificate of appreciation to Sawyers.